Cargando…
TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
PURPOSE: To investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This retrospective study examined 50 patients with huge unresectable HCC treated fr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438914/ https://www.ncbi.nlm.nih.gov/pubmed/32903854 http://dx.doi.org/10.3389/fphar.2020.01130 |
_version_ | 1783572889256067072 |
---|---|
author | Wu, Ying Qi, Han Cao, Fei Shen, Lujun Chen, Shuanggang Xie, Lin Huang, Tao Song, Ze Zhou, Danyang Fan, Weijun |
author_facet | Wu, Ying Qi, Han Cao, Fei Shen, Lujun Chen, Shuanggang Xie, Lin Huang, Tao Song, Ze Zhou, Danyang Fan, Weijun |
author_sort | Wu, Ying |
collection | PubMed |
description | PURPOSE: To investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This retrospective study examined 50 patients with huge unresectable HCC treated from January 2009 to December 2015. Among them, 28 cases received TACE-sorafenib treatment (TACE-sorafenib group), and 22 cases received TACE-sorafenib plus thermal ablation treatment (TACE-sorafenib-thermal ablation group). The Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared. RESULTS: The median follow-up was 13.5 months (ranges 4.2 to 96.7 months). The median OS was significantly longer in the TACE-sorafenib-thermal ablation group than that in the TACE-sorafenib group (20.8 vs. 10.4 months, P=0.003). The median PFS of the ablation and no ablation groups were 4.3 vs. 7.1 months (P=0.546). The treatment modality was an independent predictor of OS (P=0.004). There were no notable drug-related high grade adverse events or permanent adverse sequelae. CONCLUSION: TACE-sorafenib-thermal ablation provided extended OS to patients with huge unresectable HCC and could be a better choice than TACE-sorafenib. |
format | Online Article Text |
id | pubmed-7438914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74389142020-09-03 TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma Wu, Ying Qi, Han Cao, Fei Shen, Lujun Chen, Shuanggang Xie, Lin Huang, Tao Song, Ze Zhou, Danyang Fan, Weijun Front Pharmacol Pharmacology PURPOSE: To investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This retrospective study examined 50 patients with huge unresectable HCC treated from January 2009 to December 2015. Among them, 28 cases received TACE-sorafenib treatment (TACE-sorafenib group), and 22 cases received TACE-sorafenib plus thermal ablation treatment (TACE-sorafenib-thermal ablation group). The Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared. RESULTS: The median follow-up was 13.5 months (ranges 4.2 to 96.7 months). The median OS was significantly longer in the TACE-sorafenib-thermal ablation group than that in the TACE-sorafenib group (20.8 vs. 10.4 months, P=0.003). The median PFS of the ablation and no ablation groups were 4.3 vs. 7.1 months (P=0.546). The treatment modality was an independent predictor of OS (P=0.004). There were no notable drug-related high grade adverse events or permanent adverse sequelae. CONCLUSION: TACE-sorafenib-thermal ablation provided extended OS to patients with huge unresectable HCC and could be a better choice than TACE-sorafenib. Frontiers Media S.A. 2020-07-29 /pmc/articles/PMC7438914/ /pubmed/32903854 http://dx.doi.org/10.3389/fphar.2020.01130 Text en Copyright © 2020 Wu, Qi, Cao, Shen, Chen, Xie, Huang, Song, Zhou and Fan http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wu, Ying Qi, Han Cao, Fei Shen, Lujun Chen, Shuanggang Xie, Lin Huang, Tao Song, Ze Zhou, Danyang Fan, Weijun TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma |
title | TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma |
title_full | TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma |
title_fullStr | TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma |
title_full_unstemmed | TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma |
title_short | TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma |
title_sort | tace-sorafenib with thermal ablation has survival benefits in patients with huge unresectable hepatocellular carcinoma |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438914/ https://www.ncbi.nlm.nih.gov/pubmed/32903854 http://dx.doi.org/10.3389/fphar.2020.01130 |
work_keys_str_mv | AT wuying tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma AT qihan tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma AT caofei tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma AT shenlujun tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma AT chenshuanggang tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma AT xielin tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma AT huangtao tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma AT songze tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma AT zhoudanyang tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma AT fanweijun tacesorafenibwiththermalablationhassurvivalbenefitsinpatientswithhugeunresectablehepatocellularcarcinoma |